Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata. (2026). SKIN The Journal of Cutaneous Medicine, 10(2), s768. https://doi.org/10.25251/bqftmw67